GENF.LSE Genflow Biosciences plc

Healthcare Biotechnology London Exchange
0.0190 GBX
Close of Nov 3, 2026
1.21 3.12
Market cap
GBX 11.3M
P/E
-
P/B
57.15x
ROE
-442.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is GENF.LSE undervalued?

Graham number

The Graham number of Genflow Biosciences plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Genflow Biosciences plc fundamental analysis

No fundamental analysis for Genflow Biosciences plc yet.

Genflow Biosciences plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Genflow Biosciences plc

Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapies in the United Kingdom, Belgium, and the United States. It develops drugs in pre-clinical trial stage, including GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion for the treatment of metabolic associated steatohepatitis; GF-1003, a topical delivery of SIRT6 to the skin; GF-1004, a non-human pipeline anti-aging …

Full company profile